The re-import of penicillins or streptomycins in dosage forms to France is exhibiting a declining trend based on the forecasted data from 2024 to 2028, with values decreasing modestly year on year. The figures for 2023, which reflect the actual data, stand as a benchmark for this forecast. On a yearly basis, a slight decline is anticipated, with each year showcasing a reduction of approximately 0.61%. Over a five-year span, the Compound Annual Growth Rate (CAGR) suggests a gradual downward trajectory, highlighting consistent attenuation in import values.
Future trends to watch for include the impact of global antibiotic drug demand fluctuations, potential changes in trade policies and agreements, and advancements in pharmaceutical technologies affecting re-import requirements. Additionally, watch for shifts in local manufacturing capabilities within France that could influence the need for re-importation.
